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Abstract
Fibulin-1 (FBLN-1) is a secreted glycoprotein that is associated with extracellular matrix (ECM) formation and rebuilding.
Abnormal and exaggerated deposition of ECM proteins is a hallmark of many fibrotic diseases, such as chronic obstructive
pulmonary disease (COPD) where small airway fibrosis occurs. The aim of this study was to investigate the regulation of
FBLN-1 by transforming growth factor beta 1 (TGF-b1) (a pro-fibrotic stimulus) in primary human airway smooth muscle
(ASM) cells from volunteers with and without COPD. Human ASM cells were seeded at a density of 16104 cells/cm2, and
stimulated with or without TGF-b1 (10 ng/ml) for 72 hours before FBLN-1 deposition and soluble FBLN-1 were measured.
Fold change in FBLN-1 mRNA was measured at 4, 8, 24, 48, 72 hours. In some experiments, cycloheximide (0.5 mg/ml) was
used to assess the regulation of FBLN-1 production. TGF-b1 decreased the amount of soluble FBLN-1 both from COPD and
non-COPD ASM cells. In contrast, the deposition of FBLN-1 into the ECM was increased in ASM cells obtained from both
groups. TGF-b1 did not increase FBLN-1 gene expression at any of the time points. There were no differences in the TGF-b1
induced FBLN-1 levels between cells from people with or without COPD. Cycloheximide treatment, which inhibits protein
synthesis, decreased both the constitutive release of soluble FBLN-1, and TGF-b1 induced ECM FBLN-1 deposition.
Furthermore, in cycloheximide treated cells addition of soluble FBLN-1 resulted in incorporation of FBLN-1 into the ECM.
Therefore the increased deposition of FBLN-1 by ASM cells into the ECM following treatment with TGF-b1 is likely due to
incorporation of soluble FBLN-1 rather than de-novo synthesis.
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Introduction
Chronic obstructive pulmonary disease (COPD), a common
preventable and treatable disease, is characterised by airflow
limitation that is usually progressive and associated with an
enhanced chronic inflammatory response in the airways and the
lung to noxious particles or gases [1]. It is known that the
extracellular matrix (ECM) is altered in the airway walls of patients
with COPD [2,3]. Increased airway thickening and narrowing
occurs in the small airways of smokers with COPD, which is the
main reason for respiratory obstruction [4,5,6,7].
The ECM is a complex structured network of secreted
macromolecules and proteolytic enzymes that provide the basis
of cell-cell and cell-matrix interactions. In the lung, ECM
components fundamentally influence the structure and function
of airways. Abnormal and exaggerated deposition of the ECM is a
hallmark of many fibrotic diseases, such as COPD. Fibulin-1
(FBLN-1) is a secreted glycoprotein that is associated with ECM
formation and rebuilding. FBLN-1 is expressed in basement
membranes, microfibrils and elastic fibres [8], and also is
associated with various ECM proteins such as fibronectin (FN),
nidogen-1, and laminin-1 [9,10,11,12]. However, the role of
FBLN-1 in the aetiology and pathology of fibrosis is unclear. We
have previously found elevated FBLN-1 in the serum and lung
washing fluid (bronchoalveolar lavage) of people with asthma, and
furthermore shown FBLN-1 to regulate airway smooth muscle
(ASM) cell proliferation, therefore highlighting the potential role of
FBLN-1 in airway wall remodelling [13].
Transforming growth factor beta 1 (TGF-b1) is a pro-fibrotic
cytokine which is increased in several forms of acute and chronic
adult lung diseases such as asthma [14], COPD [15,16], and
pulmonary fibrosis [17,18]. It is considered to play a crucial role in
the pathogenesis of tissue fibrosis, stimulating the production of
various collagens and ECM proteins [19,20,21]. The regulation of
ECM production by TGF is often different between primary
mesenchymal lung cells from people with fibrotic lung diseases in
comparison to those without. For example we have previously
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found that TGF-b1 increased perlecan from COPD ASM cells
only [22].
This study aimed to investigate the regulation of FBLN-1 by
TGF-b1 in primary human ASM cells from volunteers with or
without COPD. We hypothesized that the pro-fibrotic cytokine
TGF-b1 would up regulate the deposition of FBLN-1, with greater
production observed in cells from people with COPD incompar-
ison to cells from people without lung disease.
Materials and Methods
Ethics Statement
Approval of all experiments with human lung tissues was
provided by the Ethics Review Committee of the South West
Sydney Area Health Service, St Vincent’s Hospital Sydney,
Strathfield Private Hospital, Royal Prince Alfred Hospital, and the
University of Sydney Human Research Ethics Committee. All
volunteers or their next of kin provided written informed consent.
Study Population
Samples obtained from a total of 17 volunteers with COPD and
19 volunteers without COPD were studied. COPD was diagnosed
according to current guidelines including dyspnea, chronic cough
or sputum production, a history of exposure to risk factors for the
disease, and spirometry [1]. Those in the COPD group had a
forced expiratory volume in one second (FEV1)/forced vital
capacity (FVC) #0.7 indicating airflow limitation. The non-
COPD group had a FEV1/FVC .0.7 and FEV1$80%. The
details of all individuals from whom tissue was obtained are
provided in table 1.
Isolation of Human ASM Cells
Human ASM cells were isolated from lung tissue obtained from
donors undergoing resection for either thoracotomy or transplan-
tation. Methods for isolation of the cells were described previously
[23]. In short, bronchial airways were dissected from the
surrounding lung tissue and cut longitudinally. Subsequently, the
airways were washed in 80% ethanol and Hank’s balanced salt
solution (Invitrogen, Carlsbad, CA, USA) before being dissected
under a dissecting microscope. Isolated smooth muscle bundles
were cut into pieces and placed into 25 cm2 tissue culture flasks
(BD Biosciences, North Ryde, Australia) containing 2.5 ml
Dulbecco’s modified eagle’s medium (DMEM) (Invitrogen) sup-
plemented with 10% foetal bovine serum (FBS) (DKSH,
Melbourne, AUS), 2% antibiotics (Invitrogen), 25 mM Hepes
(Invitrogen) and 5 mg/ml plasmocin (InvivoGen, San Digo, CA,
USA) and placed in a humidified CO2 incubator (37uC/5% CO2).
Twice a week, the medium was aspirated and replaced with fresh
DMEM supplemented with 5% FBS, 1% antibiotics and 25 mM
Hepes (growth medium). Cells used for experiments between
passages 2 and 7, and all the cells tested negative for the presence
of mycoplasma before they were set up for experiments.
ASM Cell Culture
ASM cells were seeded in 6-well plates and 96-well plates at a
density of 16104 cells/cm2 in growth medium and incubated at
37uC/5% CO2. After 72 hours, cells were quiesced in DMEM
supplemented with 0.1% FBS, 1% antibiotics and 25 mM Hepes
(Quiescing medium) for 24 hours then treated with or without
10 ng/ml of TGF-b1 (R&D Systems, Minneapolis, MN, USA) in
quiescing medium for 4, 8, 24, 48 (RNA analysis) and 72 hours
(RNA and protein analysis). RNA samples were stored at 280uC,
and supernatant and protein samples were stored at 220uC until
analysis.
RNA Extraction and Real Time Polymerase Chain Reaction
(PCR)
Total RNA was collected over a time course (4, 8, 24, 48, 72
hours) using the ISOLATE RNA Mini kit (Bioline, London, UK)
according to the manufacturer’s instructions. RNA was eluted in
50 ml of RNase free water. mRNA was converted to cDNA by
using M-MLV reverse transcriptase (Invitrogen) according to the
manufacturer’s instructions. For the detection of FBLN-1 and FN
gene expression the primers were used as follows: FBLN-1
Hs00243545_ml and FN Hs00365058_ml (Invitrogen) [13]. For
quantitative analysis of gene expression, human 18S rRNA
(Invitrogen) was used as an endogenous control. The thermal
cycle conditions consisted of 40 cycles of 95uC for 15 seconds and
60uC for 1 minute [24]. Real time PCR was performed using the
StepOne Plus detection system, data were collected and analysed
by StepOne software (Applied Biosystems, Melbourne, AUS). The
relative abundance of mRNA was calculated by using the DDCt
method [25], and results were normalized to 18S rRNA.
ECM Enzyme-linked Immune Sorbent Assay (ELISA)
Human ASM cells were seeded in 96-well plates as described
above. After stimulation with or without 10 ng/ml TGF-b1 for 72
hours, ASM cells were lyzed with 0.016 mM NH2OH at 37uC for
20 minutes. The cell free ECM plates were washed three times
with 0.05% phosphate buffered saline (PBS)-Tween (vol/vol) and
stored with 100 ul/well of PBS at 220uC until analysis. The
deposition of protein in the ECM was measured by ELISA
according to the method described previously [26]. Briefly, ECM
plates were defrosted at room temperature, and non-specific
bound molecules were removed by blocking with 1% BSA in PBS
(Sigma Aldrich, St Louis, MO, USA). All antibodies were diluted
in 1% BSA/PBS-Tw and added at 50 ml/well. Mouse monoclonal
anti-human FBLN-1 antibody (0.07 mg/ml) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and mouse monoclonal anti-
human FN C-terminal antibody (2 mg/ml) (Millipore, Billerica,
MA, USA) were used as primary antibodies. Mouse IgG1,k (BD
Biosciences, Franklin Lakes, NJ, USA) and mouse IgG2a (Dako,
Glostrup, DK) were used as isotype controls respectively. For
measurement of FBLN-1 or its isotype control, a biotinylated
chicken anti-mouse antibody (8 mg/ml) (Santa Cruz) was used
followed by streptavidin-horseradish peroxidase (streptavidin-
HRP) (1:200 dilution) (R&D Systems). Rabbit anti-mouse Ig-
HRP (2.6 mg/ml) (Dako) was used as a secondary antibody for the
measurement of FN and its isotype control. After final washing,
50 ml/well of chromogenic substrate 3,39,5,59-tetramethylbenzi-
dine (TMB) was added, the reaction was stopped by 50 ml/well of
1M N2HPO3 and absorbance was read at 450 nm–570 nm using
a spectrophotometer and software (Spectramax M2 and Soft Max
pro 4.8, Molecular Devices, Sunnyvale, CA, USA).
Protein Extraction and Western Blots
Human ASM cells were seeded in 6-well plates as described
above, after stimulation with or without 10 ng/ml TGF-b1,
supernatant and total cellular protein were collected and stored at
220uC until analysis. Total cellular protein was extracted by using
extracting buffer which contained 20 mM Tris, pH 7.4, 150 mM
NaCl, 1 mM Na2EDTA, 1% Triton X-100, 10% glycerol, 0.1%
SDS, 0.5% sodium deoxycholate, 1% protease inhibitor cocktail
set III (Millipore) and 1 mM phenylmethylsulfonyl fluoride
(PMSF) (Amresco, Solon, OH, USA). Cell lysates were collected
and centrifuged at 4uC/14,000 g for 10 minutes to pellet cell
debris. Total protein concentration was measured by Bio-Rad
protein assay (Bio-Rad, Hercules, CA) according to the manufac-
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turer’s instructions. Soluble FBLN-1 or FN and cellular FBLN-1
or FN were detected by western blots which were performed as
described previously [27]. Proteins were size fractionated on 10%
polyacrylamide gels, transferred to polyvinylidene fluoride (PVDF)
membranes, and blocked in 5% (wt/vol) skim milk solution for 1
hour. The membranes were incubated with primary antibody
(0.4 mg/ml of mouse monoclonal anti-human FBLN-1 antibody in
2% BSA/TBS-Tw) for 2 hours, followed by incubation with
secondary antibody (2.6 m/ml of rabbit anti-mouse Ig-HRP
antibody in 2% BSA/TBS-Tw) for 1 hour. Immunoblot detection
was performed using Immobilon Western Chemiluminescent
HRP Substrate (Millipore) and bands were analysed by using
Kodak image station 4000 MM, and the amount of protein
present in each sample was determined as the densitometric
density. Glyceraldehyde 3-phophate dehydrogenase (GAPDH)
was used as a loading control, the amount of FBLN-1 or FN was
normalized to GPADH detected on the same membrane, and
results were expressed as fold change relative to control.
Inhibition of New Protein Synthesis
Cycloheximide treatment was performed as described previ-
ously [28]. In short, human ASM cells were treated with 0.5 mg/
Table 1. Characteristics of volunteers.
Surgery Diagnosis Age, yr Gender Smoker FEV1:FVC FEV1% FVC %
1 T Emphysema 54 M Y 0.26 14 44
2 T Emphysema 53 M Y 0.34 23 55
3 T Emphysema 51 F Y 0.27 22 67
4 T Emphysema 45 F Y 0.24 21 69
5 T Emphysema 67 M Y 0.24 13 44
6 T Emphysema 57 F Y 0.33 24 59
7 T Emphysema 51 F Y 0.25 18 57
8 T Emphysema 60 M Y 0.25 9 30
9 R COPD 59 M Y 0.74 69 71
10 R COPD/NSCCa 64 M Y 0.60 56 73
11 R COPD/NSCCa 58 M Y N/A 70 N/A
12 R COPD/SCCa 71 M Y 0.55 44 64
13 R NSCCa 60 M Y 0.60 77 97
14 R NSCCa 72 M Y 0.74 51 53
15 R Adeno Ca 56 F Y 0.74 66 71
16 R Neoplasm 68 F Y 0.67 72 81
17 T Sarcoidosis 43 M Y 0.55 31 45
18 B Normal 22 F Y 0.94 86 91
19 B Normal 29 M N 0.84 86 84
20 B Normal 22 F N/A N/A N/A N/A
21 B Normal 27 F N N/A N/A N/A
22 T Normal 16 M N/A N/A N/A N/A
23 B Normal 69 M N/A N/A N/A N/A
24 N/A Normal 27 M N N/A N/A N/A
25 R NSCCa 72 M Y 0.72 83 89
26 R NSCCa 63 M Y 0.85 68 64
27 R NSCCa 59 M Y 0.78 75 73
28 R NSCCa 73 F Y 0.74 100 113
29 R NSCCa 70 F Y 0.68 64 92
30 R NSCCa 65 M Y 0.78 92 93
31 R NSCLC 70 M Y 0.73 85 88
32 R Ca 78 F Y 0.76 88 95
33 R Ca 61 M Y 0.75 101 107
34 T IPF 55 M Y 0.88 39 35
35 T IPF 58 M Y 0.88 52 44
36 T IPF 65 M Y 0.74 30 32
T, transplant; R, resection; B, bronchoscopy; M, male; F, female; Y, yes; N, no; N/A, not available; FEV1%, forced expiratory volume in 1 second of predicted %; FVC%,
forced vital capacity of predicted %; Ca, carcinoma; SCCa, small cell carcinoma; NSCCa, non-small cell carcinoma; NSCLC: non-small cell lung carcinoma; IPF: idiopathic
pulmonary fibrosis.
doi:10.1371/journal.pone.0065544.t001
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ml cycloheximide or vehicle (DMSO) for 1 hour. Medium was
aspirated from each well then cells were treated with or without
10 ng/ml TGF-b1 in the presence of cycloheximide or vehicle.
After 72 hours, supernatant and cell free ECM plates were
harvested and stored at 220uC for assessment of ECM proteins.
Separately, another set of cells was counted for estimation of total
number.
Addition of Soluble FBLN-1
Supernatant from human ASM cells treated with quiescing
medium for 72 hours was used as a source of soluble FBLN-1
containing medium. Human ASM cells were seeded in 96-well
plates, grown and quiescenced as described before. Cells were pre-
treated with 0.5 mg/ml cycloheximide for 1 hour then the medium
was changed to a quiescing one or soluble FBLN-1 containing
medium in the presence of cycloheximide with or without 10 ng/
ml TGF-b1. After 72 hours, the cell free ECM plates were
harvested and stored at 220uC for assessment of ECM proteins.
Statistical Analysis
Data analysis was performed using GraphPad Prism 5.0
software (GraphPad Software, San Diego, CA, USA). All the
data were expressed as mean6 standard error of the mean (SEM).
Statistical significance was determined by paired t-test, one-way
analysis of variance (one-way ANOVA) or two-way analysis of
variance (two-way ANOVA) where appropriate, followed by
Bonferroni post test. A p value of less than or equal to 0.05
(p#0.05) was considered significant.
Results
TGF-b1 Up Regulated the Deposition of FBLN-1 into the
ECM Produced by Both COPD and Non-COPD ASM Cells
Following 72 hours stimulation with 10 ng/ml TGF-b1, the
deposition of FBLN-1 was significantly increased in ASM cells
obtained from volunteers with COPD (p,0.01, n = 10) and
without COPD (p,0.01, n= 7) (Fig. 1A). TGF-b1 also increased
the deposition of FN in ASM cells from both groups (COPD,
p,0.01, n = 12 and non-COPD, p,0.05, n = 11) (Fig. S1A).
There were no differences between COPD and non-COPD ASM
cells in the deposition of FBLN-1 or FN either basally or after
treatment with TGF-b1 (Fig. 1A, Fig. E1A).
TGF-b1 up Regulated Cellular FBLN-1 in Both COPD and
Non-COPD ASM Cells
As the deposition of FBLN-1 into the ECM was increased by
TGF-b1, cellular FBLN-1 was assessed by western blotting to
confirm this up regulation. After 72 hours of stimulation with
10 ng/ml TGF-b1, the FBLN-1 was significantly up regulated in
both COPD (p,0.001, n= 8) and non-COPD (p,0.05, n= 7)
ASM cells, and there was no difference between the COPD and
non-COPD groups in the fold change of cellular FBLN-1 induced
by TGF-b1 (Fig. 1B, 1C). The amount of cellular FN was
increased by TGF-b1 in human ASM cells (p,0.05, n= 6) (Fig.
S1B, S1C).
TGF-b1 Decreased Soluble FBLN-1 Levels in Supernatants
from COPD and Non-COPD ASM Cells
Since it’s already known that FBLN-1 exists in both solid
(ECM) and soluble forms, we also measured soluble FBLN-1 in
supernatants from human ASM cells. Following 72 hours
stimulation with 10 ng/ml TGF-b1, the level of soluble
FBLN-1 was significantly decreased in supernatant from COPD
(p,0.001, n= 9) and non-COPD (p,0.001, n = 9) ASM cells,
and there was on differences in the fold change of soluble
FBLN-1 decreased by TGF-b1 between the two groups (Fig. 2A,
2B). In contrast, the level of soluble FN was significantly
increased in the supernatants from human ASM cells by TGF-
b1 (p,0.05, n = 8) (Fig. S2A, S2B).
Reduction of FBLN-1 mRNA Expression by TGF-b1
After stimulation with 10 ng/ml TGF-b1, FBLN-1 mRNA
expression in human ASM cells obtained from volunteers with
and without COPD gradually decreased over the time course (4,
8, 24, 48, 72 hours) (Fig. 3). At the 4 h and 8 h time points
there were no significant changes in FBLN-1 mRNA levels,
however, at 24 h, 48 h, and 72 h time points the FBLN-1
mRNA expression level was significantly down regulated by
Figure 1. TGF-b1 increased the deposited and cellular FBLN-1 in
human ASM cells. After 72 hours stimulation with 10 ng/ml TGF-b1,
the deposition of FBLN-1 by human ASM cells obtained from COPD
(black bar, n = 10) and non-COPD (grey bar, n = 7) was measured by
ELISA and data were expressed as absorbance at 450 nm–570 nm
(panel A). Cellular FBLN-1 and GAPDH from COPD and non-COPD ASM
cells were detected by western blot (panel B). Data from COPD (black
bar, n = 8) and non-COPD (grey bar, n = 7) group were normalized to
GAPDH and expressed as fold change relative to control (panel C). Data
were expressed as mean 6 SEM, two-way ANOVA with Bonferroni post
tests, **P,0.01, ***P,0.001, compared with control.
doi:10.1371/journal.pone.0065544.g001
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TGF-b1 both in COPD (p,0.001, n= 7) and non-COPD
(p,0.05, p,0.001, n= 5) ASM cells. In contrast, FN mRNA
expression gradually increased following stimulation with TGF-
b1 over the time course with significant increases at 48 h and
72 h time points in COPD (p,0.01, n= 7) ASM cells, and
significant increases at 24 h, 48 h, and 72 h time points in non-
COPD (p,0.01, n= 5) ASM cells (Fig. S3). The changes in
FBLN-1 or FN mRNA were not different between the COPD
and non-COPD groups.
Cycloheximide Inhibits New FBLN-1 Protein Synthesis
Human ASM cells were treated with 0.5 mg/ml cycloheximide
for 1 hour before stimulation. After stimulation with or without
10 ng/ml TGF-b1 in the presence of cycloheximide for 72 hours,
the amount of soluble FBLN-1 released from human ASM cells
was significantly decreased by cycloheximide compared with
vehicle control (p,0.001, p,0.01, n= 5) (Fig. 4A, 4B). Similarly,
TGF-b1 induced deposition of FBLN-1 by human ASM cells also
was significantly attenuated by cycloheximide (p,0.001, n= 5)
(Fig. 4C). Soluble and ECM FN were significantly decreased by
cycloheximide compared with vehicle control (soluble FN,
p,0.01, n= 4, ECM FN, p,0.05, p,0.01, n= 5, Figs. S4A–C).
Addition of cycloheximide did not have a significant effect on total
cell number (Fig. S5).
Soluble FBLN-1 is Incorporated into the ECM of
Cycloheximide Treated Human ASM Cells
TGF-b1 decreased FBLN-1 mRNA and soluble FBLN-1 while
increasing ECM FBLN-1. Cycloheximide decreased soluble
FBLN-1 production and TGF-b1 induced ECM FBLN-1. Next
we investigated if TGF-b1 induced ECM FBLN-1 could be
derived from soluble FBLN-1 by adding exogenous source of
FBLN-1 to human ASM cells which had been blocked from
producing FBLN-1. Cycloheximide exposed ASM cells were
treated with conditioned medium containing FBLN-1 with or
without 10 ng/ml TGF-b1. After 72 hours, the incorporation of
FBLN-1 into the ECM was significantly increased in the presence
of the conditioned medium containing FBLN-1 (p,0.05, n= 7)
(Fig. 5). However, the increased deposition of FBLN-1 was not
different in the presence or absence of TGF-b1.
Discussion
The architecture of the bronchial airway often undergoes
prominent and permanent structural changes, including alter-
ations of the molecular composition of the ECM. We hypothesized
that ASM cells from people with COPD may constitutively
produce higher levels of FBLN-1 than ASM cells from people
without COPD, and TGF-b1 stimulation would further increase
the production of FBLN-1. In the present study, we found TGF-b1
increased the deposition of ECM FBLN-1 protein by human ASM
cells from both people with COPD and without COPD, whereas
TGF-b1 decreased the soluble FBLN-1 from both COPD and
non-COPD ASM cells. To confirm that the deposition of FBLN-1
was increased, the cellular and ECM FBLN-1 was measured and
found to be increased in both COPD ASM cells and non-COPD
ASM cells by TGF-b1. Next we assessed the regulation of FBLN-1,
and found that TGF-b1 decreased FBLN-1 mRNA, and that
FBLN-1 protein production was translationally controlled. There-
fore we hypothesized that the increased ECM FBLN-1 following
TGF-b1 stimulation was due to sequestration of soluble FBLN-1
and not de-novo synthesis. As there was not a commercially
available source of FBLN-1 we exposed translationally inhibited
ASM cells to conditioned medium containing FBLN-1 and found
increased ECM FBLN-1.
Figure 2. TGF-b1 decreased soluble FBLN-1 from human ASM
cells. Soluble FBLN-1 released from human ASM cells was detected by
western blot, following 72 hours stimulation with 10 ng/ml TGF-b1
(panel A). Data from COPD (black bar, n = 9) group and non-COPD (grey
bar, n = 9) group were expressed as fold change relative to control
(panel B). Data were expressed as mean 6 SEM and analysed by two-
way ANOVA with Bonferroni post tests, ***P,0.001, compared with
control.
doi:10.1371/journal.pone.0065544.g002
Figure 3. TGF-b1 decreased FBLN-1 gene expression in human
ASM cells. COPD (black bar, n = 7) and non-COPD (grey bar, n = 5)
human ASM cells were stimulated with 10 ng/ml TGF-b1, and FBLN-1
mRNA expression was detected during the time course by real time
PCR. Results were normalized to the endogenous control (18S rRNA),
and expressed as fold change in FBLN-1 mRNA compared with time
matched control. Data were expressed as mean6 SEM and analysed by
two-way ANOVA with Bonferroni post tests, *P,0.01, ***P,0.001,
compared with time matched control.
doi:10.1371/journal.pone.0065544.g003
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We selected TGF-b1 as the stimulus to assess FBLN-1
production by human ASM cells because it is a potent inducer
of ECM proteins, including FN and perlecan [19,22], and is
considered to play a significant role in fibrosis. In this study, we
confirmed that TGF-b1 increased the expression of FN mRNA
and the production of ECM and soluble FN by human ASM cells
from people with COPD and without COPD.
Our previous studies found that TGF-b1 increased the
deposition of FBLN-1 in asthmatic ASM cells only within 24
hours [13], and TGF-b1 increased the deposition of perlecan in
COPD ASM cells only following 48 hours stimulation [22]. In this
study, after stimulation up to 72 hours, there were no differences in
the TGF-b1 induced FBLN-1 or FN between ASM cells from
people with or without COPD. This suggests that the expression
profiles of different ECM proteins, and their regulation is
inherently different in cells from people with different diseases,
however, we also have to consider the biological relevance of
stimulation of cells with TGF-b1. As TGF-b1 is increased in
COPD [15,16] it is a reasonable assumption that cells in the
COPD airways in-vivo are more likely to produce FBLN-1 in
comparison to the cells from non-diseased airways, in which TGF-
b1 level may not be raised.
To understand why ECM FBLN-1 was increased but soluble
FBLN-1 was decreased by TGF-b1, we assessed the FBLN-1
mRNA in ASM cells after stimulation with TGF-b1. FBLN-1
mRNA was gradually down regulated by TGF-b1 over the time
course of 72 hours. This reduction in FBLN-1 mRNA may be the
cause of the decreased soluble FBLN-1 protein observed following
TGF-b1 stimulation because of there was a reduction in the
amount of FBLN-1 mRNA available for transcription. However,
as the levels of FBLN-1 mRNA at the 4 h and 8 h time points was
still quite stable, which also suggested that the possibility that the
increased deposition of FBLN-1 was transcribed from the early
time point FBLN-1 mRNA, and subsequently incorporated into
the matrix.
It is still unknown whether TGF-b1 induced the deposition of
FBLN-1 into the ECM directly through the activation of the cell
surface receptors such as integrins, or if TGF-b1 increases other
ECM proteins, which may bind to soluble FBLN-1 and anchor it
in the ECM. In support of the possibility of integrin involvement, it
is known that TGF-b1-increased FN deposition occurs via an
integrin receptor on human ASM cells [19]. However, it is also
known that FBLN-1 is not incorporated into the ECM by cells
which fail to assemble FN [10], indicating that these two proteins
have a critical interaction in other cell systems. We found that FN
increased independently of increased synthesis of FBLN-1, but we
do not know if FBLN-1 is the rate limiting step in FN
incorporation into the ECM.
Figure 4. Cycloheximide inhibited soluble FBLN-1 synthesis
and down-regulated the deposition of FBLN-1 induced by TGF-
b1. After stimulation with 10 ng/ml TGF-b1 in the presence or absence
of 0.5 mg/ml cycloheximide, the soluble FBLN-1 released from human
ASM cells was detected by western blot (panel A). Data were
normalized to cell number and results were expressed as the fold
change compared with vehicle (panel B, n = 5). The deposition of FBLN-
1 from human ASM cells in different treatments was measured by ECM
ELISA and data were expressed as absorbance at 450 nm–570 nm
(panel C, n = 5). Data were expressed as mean 6 SEM and analysed by
one-way ANOVA with Bonferroni’s multiple comparison test, **P,0.01,
***P,0.001. V: vehicle; CHX: cycloheximide; T: TGF-b1.
doi:10.1371/journal.pone.0065544.g004
Figure 5. FBLN-1 from a soluble source is incorporated into the
ECM. Cycloheximide treated and untreated human ASM cells were
stimulated with or without 10 ng/ml TGF-b1 in quiescing medium or
soluble FBLN-1 containing medium for 72 hours (n = 7). The incorpo-
ration of FBLN-1 into the matrix was detected by ECM ELISA and data
were expressed as absorbance at 450 nm–570 nm. Data were
expressed as mean 6 SEM and analysed by one-way ANOVA with
Bonferroni’s multiple comparison test, *P,0.05, ***P,0.001. V: vehicle;
CHX: cycloheximide; S: soluble FBLN-1 containing medium; T: TGF-b1.
doi:10.1371/journal.pone.0065544.g005
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We used cycloheximide, which is an inhibitor of protein
biosynthesis in eukaryotic organisms, to inhibit new protein
synthesis. It exerts its effect by interfering with the translocation
step in protein synthesis (movement of two tRNA molecules and
mRNA in relation to the ribosome) thus blocking translational
elongation. In this study, the cycloheximide treatment, at a
concentration which was not cytotoxic, decreased the constitutive
release of soluble FBLN-1 and inhibited TGF-b1 induced FBLN-1
deposition in the ECM. As expected, it also inhibited the
production of soluble and deposited FN. We used soluble
FBLN-1 containing medium to treat cycloheximide treated ASM
cells in the presence or absence TGF-b1. We found that the
addition of soluble FBLN-1 increased the deposition of FBLN-1
into the ECM even in the presence of cycloheximide. This
increased deposition is unlikely to be the result of increased de-
novo synthesis of other ECM proteins as the cells were treated with
cycloheximide. However cellular processes independent of new
protein translation would still occur, such as integrin activation,
and these overall experiments indicate that soluble FBLN-1
influences the deposition of ECM FBLN-1. The increased
deposition of FBLN-1 by TGF-b1 is likely due to incorporation
of soluble FBLN-1 rather than de-novo synthesis. Furthermore as
there was no difference in ECM FBLN-1 between cells treated
with and without TGF-b1 in the presence of cycloheximide, this
suggests that the increased deposition of FBLN-1 is not simply the
result of TGF-b1 activated cell surface receptors.
In conclusion, this study demonstrates that TGF-b1 increased
FBLN-1 independent of local de-novo synthesis. As FBLN-1 is
increased in fibrotic tissues in a range of diseases and organs, this
study suggests that potentially the FBLN-1 may be derived from
cells or organs distant from those affected. Therefore soluble
FBLN-1, as is found in serum, may potentially be a novel way of
affecting the development and/or persistence of fibrosis in multiple
organs.
Supporting Information
Figure S1 TGF-b1 increased the deposited and cellular FN in
human ASM cells. After 72 hours stimulation with TGF-b1, the
deposition of FN by human ASM cells isolated from COPD (black
bar, n= 12) and non-COPD (grey bar, n= 11) was measured by
ELISA and data were expressed as absorbance at 450 nm–
570 nm (panel A). Cellular FN and GAPDH from human ASM
cells were detected by western blot (panel B). Data were
normalized to GAPDH and expressed as fold change relative to
control (n = 6, panel C). Data were expressed as mean6 SEM and
analysed by two-way ANOVA with Bonferroni post tests, and
paired t-test, *P,0.05, **P,0.01, compared with control.
(TIF)
Figure S2 TGF-b1 increased soluble FN from human ASM
cells. Soluble FN released from human ASM cells was detected by
western blot, following 72 hours stimulation with 10 ng/ml TGF-
b1 (panel A). Data were expressed as fold change relative to control
(n = 8, panel B). Data were expressed as mean 6 SEM and
analysed by paired t-test, *P,0.05, compared with control.
(TIF)
Figure S3 TGF-b1 increased FN gene expression in human
ASM cells. COPD (black bar, n= 7) and non-COPD (grey bar,
n = 5) human ASM cells were stimulated with 10 ng/ml TGF-b1,
and FN mRNA expression was detected during the time course by
real time PCR. Results were normalized to the endogenous
control (18S rRNA), and expressed as fold change in FN mRNA
compared with time matched control. Data were expressed as
mean 6 SEM and analysed by two-way ANOVA with Bonferroni
post tests, **P,0.01, compared with time matched control.
(TIF)
Figure S4 Cycloheximide inhibited soluble FN synthesis and
down-regulated the deposition of FN induced by TGF-b1. After
stimulation with 10 ng/ml TGF-b1 in the presence or absence of
0.5 ug/ml Cycloheximide, the soluble FN released from human
ASM cells detected by western blot (panel A). Data were
normalized to cell number and results were expressed as the fold
change compared with vehicle (panel B, n= 4). The deposition of
FN from human ASM cells in different treatments was measured
by ECM ELISA and data were expressed as absorbance at
450 nm–570 nm (panel C, n= 5). Data were expressed as mean 6
SEM and analysed by one-way ANOVA with Bonferroni’s
multiple comparison test, *P,0.05, **P,0.01, V: vehicle; CHX:
cycloheximide; T: TGF-b1.
(TIF)
Figure S5 Cycloheximide had no effect on total cell number.
After stimulation with 10 ng/ml TGF-b1 in the presence or
absence of 0.5 ug/ml Cycloheximide, the cell number in each
condition was counted (manual cell counts) (n = 5). Data were
expressed as mean 6 SEM and analysed by one-way ANOVA
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